Authors: McLennan,S.;McGill,M.;Twigg,S. M.;Yue,D. K.

Publication: Expert Review of Endocrinology and Metabolism

Year: 2007

Volume: 2

Issue: 2

Start Page: 205

ABSTRACT:

The prevalence of diabetes is increasing worldwide and has been forecasted to double in the next 20 years. The major increase in morbidity and mortality of diabetes is due to the development of both macro- and microvascular complications, including failure of the wound-healing process. Foot ulcers occur in 15% of all patients with diabetes and precede 84% of all lower-leg amputations. The essential components of diabetic foot ulcer treatment are to reduce foot bearing pressure (in neuropathic ulcers) and to increase blood supply (in the case of vascular ulcers). Antibacterial therapy is also important. Despite optimized treatment, for reasons not completely understood, some ulcers fail to heal. Previous research studies have shown clearly that failure of healing eventually leads to deep-seated infection and amputation. Therefore, impaired wound healing is the pivotal event responsible for most of the morbidity (and mortality) of diabetic foot disease. Improving wound healing in diabetes requires a multidisciplinary approach in terms of clinical management as well as an increased effort aimed at better understanding the pathogenesis of poor wound healing in diabetes. Consequently, a detailed understanding of the wound-healing process in diabetes and how it can be improved is of great importance. However, efforts to develop new therapies are hampered by a lack of knowledge of the molecular mechanisms responsible for the pathologies, as well as a lack of suitable models for the study of chronic wounds. Therefore, this review will address both clinical and biochemical aspects of wound healing in diabetes. © 2007 Future Drugs Ltd.

• Listing ID: 4493
• Author/s: McLennan,S.;McGill,M.;Twigg,S. M.;Yue,D. K.
• Publication: Expert Review of Endocrinology and Metabolism
• Year: 2007
• Volume: 2
• Issue: 2
• Start Page: 205
• Article Keywords: antiinfective agent;fibroblast growth factor 2;becaplermin;epidermal growth factor;growth factor;oxygen;placebo;platelet derived growth factor;platelet derived growth factor B;somatomedin;transforming growth factor alpha;transforming growth factor beta;vasculotropin;antimicrobial therapy;bioengineering;clinical protocol;clinical trial;diabetes mellitus;diabetic foot;disease model;electrostimulation;gene transfer;health care cost;health care delivery;health center;health education;human;hyperbaric oxygen;infection;leg amputation;low level laser therapy;microangiopathy;morbidity;mortality;neuropathy;nonhuman;pressure;prevalence;priority journal;review;stem cell transplantation;vacuum assisted closure;vascularization;weight bearing;wound;wound healing;wound healing impairment